Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. The company also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1988 and is headquartered in Queensbury, New York. Show more

566 Queensbury Avenue, Queensbury, NY, 12804, United States

https://www.delcath.com

Medical Devices

Healthcare

Start AI Chat

Market Cap

567M

52 Wk Range

$8.12 - $17.42

Previous Close

$16.39

Open

$16.32

Volume

491,082

Day Range

$16.15 - $16.49

Enterprise Value

474.9M

Cash

95.9M

Avg Qtr Burn

N/A

Insider Ownership

8.09%

Institutional Own.

51.77%

Qtr Updated

06/30/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
CHEMOSAT® Details Uveal melanoma	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system) Details Liver Dominant metastatic Ocular Melanoma, Metastatic Uveal Melanoma	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
HEPZATO™ Details Metastatic colorectal cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
HEPZATO/Melphalan (Liver-Directed Chemotherapy) Details Metastatic Cutaneous Melanoma With Liver Metastases	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
HEPZATO/Melphalan (Liver-Directed Chemotherapy) Details Metastatic Uveal Melanoma	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
HEPZATO™ Details Liver-Dominant Metastatic Breast Cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system) Details Intrahepatic cholangiocarcinoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.